NEW YORK (GenomeWeb News) – Advanced Biological Laboratories, a Luxembourg-based developer of informatics tools for personalized medicine, today announced that it has acquired all of the assets of Evivar Medical for an undisclosed amount.
The acquisition includes Melbourne, Australia-based Evivar's hepatitis B and C virus web-based decision support tools for clinicians and associated viral genome analysis systems SeqHepB and SeqHepC, its intellectual property portfolio, and all related commercial arrangements and operations. The SeqHepB and SeqHepC systems are used for hepatitis B and C therapy management and can be used to identify mutations present in the infected persons, including predicting resistance levels to commercially available drugs, the firms said.
"Our acquisition of Evivar Medical assets will add value and allows ABL to further expand its Virology portfolio from HIV to include Hepatitis disease management," ABL President and CEO Chalom Sayada.
The Evivar tools will complement ABL's existing data tools including its TherapyEdge, ViroScore, and DeepChek products.